Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATEN: Pembrolizumab + Paclitaxel in Advanced HR+/HER2- Breast Cancer
NCT04251169Phase 2Terminated
- Sponsor
- SOLTI
- Start
- Jul 2020
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by SOLTI. Primary endpoint: Overall Response Rate up to 33 months. Started Jul 2020; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04251169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251169.